# Bolt Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bolt-biotherapeutics

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.boltbio.com
- Total disclosed funding: $148M
- Latest round: Series C (Jul 1, 2020)
- Investors on record: 10

## About

Based in the US and founded in 2015 by Dr. Edgar G. Engleman, Bolt Biotherapeutics, Inc. is a biotechnology company that develops Boltbody, an immuno-oncology therapeutics designed to leverage the power of the innate and adaptive immune system.

Bolt Biotherapeutics, Inc. offers a broad spectrum of antibodies targeting tumor antigens on all types of cancer that applicable to any type of patient.

Bolt Biotherapeutics, Inc. expands the Executive Team and appointed Kathleen LaPorte as one of the Board of Directors.

## Funding rounds

- Series C, Jul 1, 2020, $94M — Sofinnova Investments, Novo Holdings, Vivo Capital, Pfizer Venture Investments, RA Capital Management, Rock Springs Capital, Pivotal Life Sciences, Samsara BioCapital, Surveyor Capital
- Series B, Feb 5, 2019, $54M — Novo Holdings, Vivo Capital, Pivotal Life Sciences, Nan Fung Life Sciences
- Seed, May 4, 2015, $0.6M — Vivo Capital

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Seed, Series B, Series C
- Novo Holdings — Series B, Series C
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B, Series C
- Nan Fung Life Sciences — Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series C
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Rock Springs Capital — Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series C
- Surveyor Capital — Series C